Pipeline Pivot | Viracta narrows focus to Nana-val for EBV+ lymphomas, pausing solid tumor program to streamline development and regulatory pathways |
Regulatory Clarity | FDA discussions yield potential accelerated approval filing for Nana-val in 2026, offering a clearer path to market for Viracta's lead candidate |
Financial Challenges | With $30M cash reserves and a reduced workforce, Viracta faces financial hurdles while aiming to extend runway for key clinical milestones |
Market Positioning | Explore Viracta's strategy to dominate the EBV+ lymphoma niche, balancing specialized focus against broader market opportunities |
Metrics to compare | VIRX | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipVIRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |